129 related articles for article (PubMed ID: 33567144)
1. The IHC4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020?
Harel N; Cheema S; Williams D; Ireland-Jenkin K; Fancourt T; Dodson A; Yeo B
Asia Pac J Clin Oncol; 2021 Aug; 17(4):368-376. PubMed ID: 33567144
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.
Yeo B; Zabaglo L; Hills M; Dodson A; Smith I; Dowsett M
Br J Cancer; 2015 Jul; 113(3):390-5. PubMed ID: 26180920
[TBL] [Abstract][Full Text] [Related]
3. Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri A; Smith IE; Hills M; Jones RL; Johnston SR; Dowsett M
Breast Cancer Res Treat; 2017 Jul; 164(2):395-400. PubMed ID: 28447240
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
6. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
Barton S; Zabaglo L; A'Hern R; Turner N; Ferguson T; O'Neill S; Hills M; Smith I; Dowsett M
Br J Cancer; 2012 May; 106(11):1760-5. PubMed ID: 22531639
[TBL] [Abstract][Full Text] [Related]
8. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
9. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.
Elsamany S; Elmorsy S; Alzahrani A; Rasmy A; Abozeed WN; Mohammed AA; Sherisher MA; Abbas MM; Mashhour M
Asian Pac J Cancer Prev; 2015; 16(17):7975-9. PubMed ID: 26625828
[TBL] [Abstract][Full Text] [Related]
11. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
12. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C
Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097
[TBL] [Abstract][Full Text] [Related]
13. IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.
Lakhanpal R; Sestak I; Shadbolt B; Bennett GM; Brown M; Phillips T; Zhang Y; Bullman A; Rezo A
Breast; 2016 Oct; 29():147-52. PubMed ID: 27498128
[TBL] [Abstract][Full Text] [Related]
14. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U; Gluz O; Christgen M; Kates RE; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Lorenz-Salehi F; Krabisch P; Just M; Augustin D; Liedtke C; Chao C; Shak S; Wuerstlein R; Kreipe HH; Harbeck N
Breast Cancer Res Treat; 2017 Oct; 165(3):573-583. PubMed ID: 28664507
[TBL] [Abstract][Full Text] [Related]
15. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
Sammons S; Sedrak MS; Kimmick GG
Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
[TBL] [Abstract][Full Text] [Related]
16. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
17. Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.
Bartlett JM; Christiansen J; Gustavson M; Rimm DL; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Putter H; Markopoulos CJ; Dirix LY; Seynaeve C; Rea DW
Arch Pathol Lab Med; 2016 Jan; 140(1):66-74. PubMed ID: 26717057
[TBL] [Abstract][Full Text] [Related]
18. The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
Aapro M; De Laurentiis M; Rea D; Bargallo Rocha JE; Elizalde R; Landherr L; Linderholm B; Mamounas E; Markopoulos C; Neven P; Petrovsky A; Rouzier R; Smit V; Svedman C; Schneider D; Thomssen C; Martin M
Breast; 2017 Jun; 33():191-199. PubMed ID: 28441617
[TBL] [Abstract][Full Text] [Related]
19. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
20. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]